Opus Genetics, Inc. Common Stock (IRD) Stock Price

IRDStock

$3.84+91.04%52W

Market Cap$319.47M

P/E—

PEG Ratio—

Div yield—

Beta0.78

IRD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-40.72%

Price vs S&P 500 (4W)-25.11%

VGM Score38.26

Book Value / Share (Quarterly)$0.22

P/TBV (Annual)20.69x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-29.11%

Cash Flow / Share (Quarterly)$-0.49

Price vs S&P 500 (YTD)79.12%

Net Profit Margin (TTM)-1091.82%

EPS (TTM)$-1.29

10-Day Avg Trading Volume1.91M

EPS Excl Extra (TTM)$-1.29

EPS (Annual)$-0.80

ROI (Annual)-300.97%

Gross Margin (Annual)87.50%

Net Profit Margin (5Y Avg)-2097.75%

Cash / Share (Quarterly)$1.07

Revenue Growth QoQ (YoY)-73.80%

ROA (Last FY)-98.70%

Revenue Growth TTM (YoY)-36.09%

EBITD / Share (TTM)$-0.61

ROE (5Y Avg)-156.92%

Operating Margin (TTM)-513.47%

Cash Flow / Share (Annual)$-0.50

P/B Ratio20.82x

P/B Ratio (Quarterly)9.03x

Net Income / Employee (Annual)$-1,836,700

EV / Revenue (TTM)27.08x

Net Interest Coverage (TTM)-32.83x

ROA (TTM)-174.89%

EV / EBITDA (TTM)9.18x

EPS Incl Extra (Annual)$-0.80

Current Ratio (Annual)6.43x

Quick Ratio (Quarterly)11.87x

3-Month Avg Trading Volume2.07M

52-Week Price Return91.04%

Revenue / Employee (TTM)$365,000

Tangible BV / Share (Quarterly)$38.85

P/S Ratio (Annual)22.50x

Asset Turnover (Annual)0.28x

52-Week High$7.07

Operating Margin (5Y Avg)-938.76%

EPS Excl Extra (Annual)$-0.80

26-Week Price Return-30.81%

Quick Ratio (Annual)6.20x

13-Week Price Return17.43%

Total Debt / Equity (Annual)0.07x

Current Ratio (Quarterly)12.19x

Enterprise Value$266.86M

Asset Turnover (TTM)0.16x

Book Value / Share Growth (5Y)-53.37%

Revenue / Employee (Annual)$525,800

Pretax Margin (Annual)-349.33%

Cash / Share (Annual)$0.65

3-Month Return Std Dev96.04%

Net Income / Employee (TTM)$-3,985,600

ROE (Last FY)-323.11%

Net Interest Coverage (Annual)-1.04x

EPS Basic Excl Extra (Annual)$-0.80

Receivables Turnover (TTM)3.27x

Total Debt / Equity (Quarterly)0.07x

EPS Incl Extra (TTM)$-1.29

Receivables Turnover (Annual)3.18x

ROI (TTM)-301.00%

P/S Ratio (TTM)32.41x

Pretax Margin (5Y Avg)-2097.58%

Revenue / Share (Annual)$0.23

Tangible BV / Share (Annual)$20.08

Price vs S&P 500 (52W)75.51%

Year-to-Date Return91.04%

5-Day Price Return-17.24%

EPS Normalized (Annual)$-0.80

ROA (5Y Avg)-90.83%

Net Profit Margin (Annual)-349.33%

Month-to-Date Return-20.66%

EBITD / Share (Annual)$-0.62

Operating Margin (Annual)-271.90%

LT Debt / Equity (Annual)0.07x

ROI (5Y Avg)-151.28%

LT Debt / Equity (Quarterly)0.07x

EPS Basic Excl Extra (TTM)$-1.29

P/TBV (Quarterly)10.58x

P/B Ratio (Annual)9.03x

Pretax Margin (TTM)-1091.82%

Book Value / Share (Annual)$0.22

Price vs S&P 500 (13W)14.75%

Beta0.78x

P/FCF (Annual)22.33x

Revenue / Share (TTM)$0.10

ROE (TTM)-316.35%

52-Week Low$1.70

vGradeD

gGradeF

mGradeB

vgmGradeD

IRD Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.16	-$0.08	+49.27%(+$0.08)
Q1 2026	May 12, 2026	-$0.14	-$0.75	-448.77%(-$0.61)
Q4 2025	Mar 10, 2026	-$0.10	-$0.21	-110.00%(-$0.11)
Q3 2025	Nov 12, 2025	-$0.13	-$0.25	-92.31%(-$0.12)
Q2 2025	Aug 13, 2025	-$0.26	-$0.12	+53.85%(+$0.14)

IRD Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.20

4.23

4.22

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IRDOpus Genetics, Inc. Common Stock	D	F	B	32.4x	-36.1%	—	—	$3.84
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Opus Genetics, Inc. Common Stock

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases and other retinal and refractive disorders. Its pipeline includes AAV-based gene therapies for bestrophinopathy, Leber congenital amaurosis, and retinitis pigmentosa, along with small-molecule and ophthalmic solutions for diabetic retinopathy and pupil dysfunction.

IRD Next Earnings Report

Report dateNov 11, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.15

Revenue estimate$2.08M

Also reporting on Nov 11, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

CCCCC4 Therapeutics, Inc.Biological Products
ASPIASP Isotopes Inc. Common StockIndustrial Chemicals
NLNLI Holdings, Inc.Industrial Chemicals
CGCCanopy Growth Corporation Common SharesPharmaceutical Preparations
SNDLSundial Growers Inc. Common SharesPharmaceutical Preparations
OECOrion S.A.Industrial Chemicals
GLASGlass House Brands Inc.Pharmaceutical Preparations
GEVOGevo, Inc.Industrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$1.70

High$7.07